Clinical evaluation of genetically engineered hypoallergenic rBet v 1 derivatives

International Archives of Allergy and Immunology

Volumn 118, Issue 2-4, 1999, Pages 216-217

  Pauli, G ^a,b   Purohit, A ^a   Oster, J P ^a   De Blay, F ^a   Vrtala, S ^c   Niederberger, V ^c   Kraft, D ^c   Valenta, R ^c  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b HÔPITAL CIVIL   (France)

^c NONE

Author keywords

Allergen; Immunotherapy; Intradermal tests; Modified hypoallergenic derivatives; rBet v 1

Indexed keywords

POLLEN ANTIGEN;

CLINICAL ARTICLE; CONFERENCE PAPER; GENETIC ENGINEERING; HUMAN; IMMUNOTHERAPY; INTRACUTANEOUS TEST; POLLEN ALLERGY; PRIORITY JOURNAL;

EID: 0032915070     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000024074     Document Type: Conference Paper

References (4)

1. Pauli G, Oster JP, Deviller P, Heiss S, Bessot JC, Susani M, Ferreira F, Kraft D, Valenta R: Skin testing with recombinant allergens rBet v 1 and birch profilin, rBet v 2: Diagnostic value for birch pollen and associated allergies. J Allergy Clin Immunol 1996;97:1100-1109.
2. Vrtala S, Hirtenlehner K, Vangelista L, Pastore A, Eichler HG, Sperr WR, Valent P, Ebner C, Kraft D, Valenta R: Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: Candidates for a novel form of specific immunotherapy. J Clin Invest 1997;99:1673-1681.
3. Vrtala S, Hirtenlehner K, Susani M, Hufnagl P, Binder BR, Vangelista L, Pastore A, Sperr WR, Valent P, Ebner C, Kraft D, Valenta R: Genetic engineering of recombinant hypoallergenic oligomers of the major birch pollen allergen, Bet v 1: Candidates for specific immunotherapy. Int Arch Allergy Immunol, in press.
4. Grammer LC, Shaughnessy MA, Shaughnessy JJ, Patterson R: Brief report: Evaluation of polymerized ragweed extracts by intradermal end point titration, RAST inhibition, and parallel line bioassay. J Allergy Clin Immunol 1985;76:123-127.